Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PHILOGEN Aktie jetzt für 0€ handeln | |||||
08.10. | Milan: Philogen suffers in tough session | - | Teleborsa | ||
25.09. | Milan: Major selling for Philogen | - | Teleborsa | ||
23.09. | Milan: Philogen falls | - | Teleborsa | ||
11.06. | Bristol Myers bolsters radiopharma portfolio with PhiloChem deal | 9 | BioPharma Dive | ||
11.06. | Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio | 1 | Contract Pharma | ||
11.06. | Bristol-Myers' RayzeBio signs a license deal with Philochem | 4 | Seeking Alpha | ||
11.06. | BMS' radiopharma unit builds with $1.35bn Philochem deal | 10 | pharmaphorum | ||
11.06. | Philogen S.p.A.: Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.3 | 896 | GlobeNewswire (Europe) | Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales
OTELFINGEN... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 6,110 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
QIAGEN | 42,105 | +0,59 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
NUVALENT | 97,18 | 0,00 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
COGENT BIOSCIENCES | 15,860 | -2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
RANI THERAPEUTICS | 2,880 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 189,94 | 0,00 % | Praxis Precision Medicines prices $525M public offering | ||
SUMMIT THERAPEUTICS | 18,780 | 0,00 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 20,640 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
DISC MEDICINE | 86,15 | -1,17 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
EVOTEC | 6,822 | +1,91 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
BIONTECH | 92,45 | +0,22 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
LENZ THERAPEUTICS | 33,510 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
BEAM THERAPEUTICS | 29,890 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SIONNA THERAPEUTICS | 42,630 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis | SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 23,150 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report |